Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FORMA Therapeutics has announced the advancement of a research collaboration and option agreement of tumor metabolism with Janssen Biotech by obtaining licensing payment and additional research funding.
Subscribe to our email newsletter
Janssen had executed a license agreement, which is part of the original contract signed between the companies in January 2012, and expanded the initial collaboration to include exploration into new targets.
The execution triggered additional undisclosed payments, in addition to potential future milestones and royalties on each product to FORMA.
FORMA president and CEO Steven Tregay said the expanded alliance demonstrates the company’s ability to execute and deliver quality drug programs to its partners.
"As we now take a defined program through the next stages of development for Janssen, we will be leveraging additional innovative translational insights through our strategic partnership," Tregay added.
FORMA research and development head and chief scientific officer stated Kenneth Bair said, "In order to better understand the interplay of targets within each of four areas (tumor metabolism, epigenetics, protein homeostasis and protein-protein interactions), FORMA initially selects 10 to 20 key targets in each area to examine and quickly creates novel drugs to drive a true chemical biology approach."